Stent to treat pancreatic cysts approved

December 19, 2013

(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said in a news release.

The pancreas, found in the upper abdomen behind the stomach, produces insulin that helps regulate and helps digestion. If pancreatic ducts become blocked from gallstones or injury, enzymes that back up into the organ can cause formation of pancreatic pseudocysts.

Most resolve on their own, but some become infected and can lead to a life-threatening blood infection, the FDA said.

The Axios stent is a wire mesh tube that can expand to more than 1/2-inch diameter. It was evaluated among 33 clinical study participants who had a pancreatic pseudocyst at least six centimeters in diameter. Some 86 percent of pseudocysts treated shrank by half or more, the FDA said.

The most common side effects of the stent included , nausea and vomiting.

The device is produced by Xlumena Inc. of Mountain View, Calif.

Explore further: Two pancreatic-enzyme products approved

More information: Visit Medline Plus to learn more about pancreatic pseudocysts.

Related Stories

Two pancreatic-enzyme products approved

March 2, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Signifor approved for Cushing's disease

December 17, 2012

(HealthDay)—Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery.

Gattex approved for short bowel syndrome

December 22, 2012

(HealthDay)—Gattex (teduglutide) has been approved by the U.S. Food and Drug Administration to treat nutritional problems caused by short bowel syndrome.

Imbruvica approved for mantle cell lymphoma

November 13, 2013

(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.

Recommended for you

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.